Explore

Discover daily Discover daily
Pay-for-Performance Still Faces a Quality Measurement Problem

Pay-for-Performance Still Faces a Quality Measurement Problem

Pay-for-performance (P4P) in healthcare, also known as value-based purchasing, is a payment model that aims to improve healthcare quality by offeri...
Rapid Read Rapid Read
Study Highlights Risks of Polypharmacy in Older Adults, Calls for Medication Review

Study Highlights Risks of Polypharmacy in Older Adults, Calls for Medication Review

A recent study published in the Rambam Maimonides Medical Journal highlights the risks associated with polypharmacy, a condition where individuals are prescribed multiple medications for various chronic conditions. The study emphasizes the potential for adverse reactions and the importance of deprescribing to improve patient outcomes. Researchers reviewed 79 studies and concluded that a multidisciplinary team should regularly review patients' medication regimens to identify inappropriate prescriptions and reduce harm. This approach could enhance the quality of life for older adults and reduce healthcare costs. The study also notes that polypharmacy is prevalent among older adults, particularly in Israel, where life expectancy is high.
Rapid Read Rapid Read
Study Warns of Harmful Effects of Polypharmacy in Older Adults

Study Warns of Harmful Effects of Polypharmacy in Older Adults

A recent study published in the Rambam Maimonides Medical Journal highlights the risks associated with polypharmacy, particularly among older adults. Polypharmacy, the practice of prescribing multiple medications to treat various chronic conditions, can lead to adverse reactions and increased healthcare costs. The study emphasizes the importance of deprescribing, which involves reducing unnecessary medications to improve patient outcomes. Researchers found that older adults are especially vulnerable to the negative effects of polypharmacy due to age-related changes in drug metabolism and the presence of multiple chronic conditions. The study calls for healthcare professionals to play a crucial role in reviewing and managing medication regimens to prevent inappropriate prescriptions.
Trendline Trendline
Digital Orchestration Transforms Regulatory Frameworks for Cell and Gene Therapy

Digital Orchestration Transforms Regulatory Frameworks for Cell and Gene Therapy

Digital Orchestration Transforms Regulatory Frameworks for Cell and Gene Therapy
Rapid Read Rapid Read
Study Warns of Risks from Polypharmacy in Older Adults

Study Warns of Risks from Polypharmacy in Older Adults

A recent study published in the Rambam Maimonides Medical Journal highlights the risks associated with polypharmacy, particularly in older adults. Polypharmacy, the practice of prescribing multiple medications to treat various chronic conditions, is prevalent among older populations, with significant risks of adverse reactions. The study emphasizes the importance of deprescribing, which involves reducing unnecessary medications to improve patient outcomes and reduce hospitalizations. The research, conducted by Dr. Carla Matos and Cindy Pinheiro, underscores the role of healthcare professionals in managing medication regimens to prevent harmful effects. The study also notes the growing population of older adults globally, with Israel having one of the highest life expectancies, further complicating the issue.
Trendline Trendline
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Develop Oral Enzyme Therapy for Pancreatic Insufficiency

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Develop Oral Enzyme Therapy for Pancreatic Insufficiency

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Develop Oral Enzyme Therapy for Pancreatic Insufficiency
Trendline Trendline
FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months
Trendline Trendline
Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength
Rapid Read Rapid Read
FDA's Project Optimus Drives Dose Optimization in Oncology Trials

FDA's Project Optimus Drives Dose Optimization in Oncology Trials

The FDA's Project Optimus, launched five years ago, remains a focal point in oncology research, as discussed at the AACR 2026 conference. The initiative aims to improve dose selection in early-phase oncology trials by balancing efficacy, safety, and tolerability. Traditional dose-finding methods, which escalate doses until toxicity is intolerable, are being reevaluated in light of new treatment modalities like targeted therapies and immunotherapies. The FDA encourages more structured, comparative evidence generation to support dose selection, emphasizing patient-reported outcomes to better capture tolerability.
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Rapid Read Rapid Read
FDA Approves Regeneron's Otarmeni for Genetic Hearing Loss, Offering Free Access in the U.S.

FDA Approves Regeneron's Otarmeni for Genetic Hearing Loss, Offering Free Access in the U.S.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Regeneron Pharmaceuticals for Otarmeni, a gene therapy designed to treat severe-to-profound sensorineural hearing loss. This therapy is specifically targeted at individuals with biallelic variants in the OTOF gene, who have preserved outer hair cell function and no prior cochlear implant in the same ear. The approval is based on data from the Phase I/II CHORD trial, which demonstrated significant improvements in hearing sensitivity among participants. Otarmeni is the first in vivo gene therapy for OTOF-related hearing loss and will be provided for free in the U.S. by Regeneron.
Trendline Trendline
Rznomics Receives FDA RMAT Designation for RZ-001 in Liver Cancer Treatment

Rznomics Receives FDA RMAT Designation for RZ-001 in Liver Cancer Treatment

Rznomics Receives FDA RMAT Designation for RZ-001 in Liver Cancer Treatment